VEGFA and glioblastoma: BEV, an inhibitor of vascular endothelial growth factor (VEGF), was approved for the treatment of multiple cancers by the Food and Drug Administration (FDA), and after two phase 2 clinical trials, in 2009, the FDA approved BEV for the treatment of recurrent GBM.38, 39